Health Discovery Corporation (OTCBB: HDVY)
announced today that the Company has entered into an exclusive agreement
with the Pancreas, Biliary and Liver Surgery Center of New York at Saint
Vincent Catholic Medical Centers in New York City to provide clinical
specimens to be utilized to complete the final validation of HDC's
molecular diagnostic test for colon cancer. This test demonstrated a 93%
Sensitivity and a 93% Specificity in a previous validation study.
“If we are successful in finding the molecular
signature in blood as we were in tissue, HDC will have both a
tissue-based colon cancer test to be used on biopsy specimens as well as
a blood test which can be used as a screening test for colon cancer”
Today’s announcement is in addition to last week’s press release
announcing a new collaboration with the Pancreas, Biliary and Liver
Surgery Center of New York related to the discovery of a new molecular
diagnostic test for pancreatic cancer.
There are an estimated 1.2 million new cases of colorectal cancer
worldwide and approximately 637,000 deaths from the disease.
“We are very excited about the results of our previous validation study
and look forward to achieving the same success in this final
validation," said Stephen D. Barnhill, M.D., Chairman and CEO of Health
Discovery Corporation. “If we are successful in finding the molecular
signature in blood as we were in tissue, HDC will have both a
tissue-based colon cancer test to be used on biopsy specimens as well as
a blood test which can be used as a screening test for colon cancer,”
said Dr. Barnhill.